论文部分内容阅读
[目的]观察奥施康定(盐酸羟考酮)联合塞来昔布治疗中、重度癌痛的临床疗效、不良反应及患者生活质量改善情况。[方法]回顾性分析110例中、重度癌痛患者,对照组(n=57)以奥施康定5mg/12h或10mg/12h为起始剂量,按25%~50%递增剂量直至达到维持剂量;治疗组(n=53)奥施康定采用相同起始剂量,再加用塞来昔布200mg/12h,若数字分级法(NRS)评分≥4,则增加至400mg/12h,若24h内仍然NRS≥4则增加奥施康定剂量直至维持剂量(NRS<3),对比分析两组患者的疼痛缓解情况、主要不良反应、药物成瘾性以及患者生活质量的改善情况。[结果]镇痛效果相同情况下,治疗组平均维持剂量低于对照组(P=0.042),治疗组便秘的发生率较对照组明显减少(P=0.017),两组患者的生活质量均有所改善。[结论]奥施康定联合塞来昔布能有效控制中、重度癌痛,提高晚期肿瘤患者的生活质量,同时奥施康定相关的不良反应发生率也有所下降。
[Objective] To observe the clinical curative effect, adverse reaction and improvement of quality of life of Oxycodone (oxycodone hydrochloride) combined with celecoxib in the treatment of moderate and severe cancer pain. [Methods] A total of 110 patients with moderate to severe cancer pain were retrospectively analyzed. The control group (n = 57) was started with Oxycodin 5mg / 12h or 10mg / 12h and the dose was increased 25% ~ 50% until the maintenance dose ; Treatment group (n = 53) OxyContin with the same initial dose, plus celecoxib 200mg / 12h, if the numerical classification method (NRS) score ≥ 4, then increased to 400mg / 12h, if 24h still NRS ≥ 4 increased the dose of OxyContin until the maintenance dose (NRS <3). The pain relief, major side effects, drug addiction and quality of life of the two groups were compared. [Results] Under the same analgesic effect, the average maintenance dose in the treatment group was lower than that in the control group (P = 0.042). The incidence of constipation in the treatment group was significantly lower than that in the control group (P = 0.017) Improved. [Conclusion] OxyContin combined with celecoxib can effectively control moderate and severe cancer pain, improve the quality of life of patients with advanced cancer, and reduce the incidence of OxyContin-related adverse reactions.